2022 ASH Annual Meeting & Exposition
View highlights from the 64th American Society of Hematology Annual Meeting & Exposition (ASH 2022), featuring combination therapy outcomes, updates on oral therapies, findings among CLL and GVHD patients, and more.
Patients who recover from grade 3-4 acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic cell ...
Researchers, led by Mark A. Schroeder, MD, conducted a single-arm, open-label phase 1 trial to evaluate the safety of ...
Haploidentical blood and marrow transplantation (BMT) has significantly increased the number of eligible hematopoietic ...
At the 64th ASH Annual Meeting and Exposition, researchers presented early findings from the dose-finding portion of ...
Chronic lymphocytic leukemia (CLL), a cancer of the blood and bone marrow that progresses over time, is one of the most ...
Chronic lymphocytic leukemia (CLL) is a cancer of the blood and bone marrow that progresses over time. The number of ...
Advertisement
Previous Updates From ASH
Coverage of the 63rd American Society of Hematology Annual Meeting & Exposition (ASH 2021)
Coverage of the 62nd American Society of Hematology Annual Meeting & Exposition (ASH 2020)
The 60th American Society of Hematology Annual Meeting & Exposition (ASH 2018)
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.